KR20200058583A - 항-cd19 항체 및 질소 머스타드를 사용한 조합 요법 - Google Patents

항-cd19 항체 및 질소 머스타드를 사용한 조합 요법 Download PDF

Info

Publication number
KR20200058583A
KR20200058583A KR1020207014299A KR20207014299A KR20200058583A KR 20200058583 A KR20200058583 A KR 20200058583A KR 1020207014299 A KR1020207014299 A KR 1020207014299A KR 20207014299 A KR20207014299 A KR 20207014299A KR 20200058583 A KR20200058583 A KR 20200058583A
Authority
KR
South Korea
Prior art keywords
ser
seq
leu
val
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020207014299A
Other languages
English (en)
Korean (ko)
Inventor
유타 아멜스도르페르
슈테판 슈테이들
마르크 빈테리히
수잔 크론
리사 로즈크예르
Original Assignee
모르포시스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 모르포시스 아게 filed Critical 모르포시스 아게
Publication of KR20200058583A publication Critical patent/KR20200058583A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020207014299A 2011-08-16 2012-08-14 항-cd19 항체 및 질소 머스타드를 사용한 조합 요법 Withdrawn KR20200058583A (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201161523861P 2011-08-16 2011-08-16
EP11177658 2011-08-16
US61/523,861 2011-08-16
EP11177658.9 2011-08-16
US201261647539P 2012-05-16 2012-05-16
US61/647,539 2012-05-16
US201261654097P 2012-06-01 2012-06-01
US61/654,097 2012-06-01
PCT/EP2012/065906 WO2013024097A1 (en) 2011-08-16 2012-08-14 Combination therapy with an anti - cd19 antibody and a nitrogen mustard

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197026462A Division KR102115203B1 (ko) 2011-08-16 2012-08-14 항-cd19 항체 및 질소 머스타드를 사용한 조합 요법

Publications (1)

Publication Number Publication Date
KR20200058583A true KR20200058583A (ko) 2020-05-27

Family

ID=47714801

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020207014299A Withdrawn KR20200058583A (ko) 2011-08-16 2012-08-14 항-cd19 항체 및 질소 머스타드를 사용한 조합 요법
KR1020197026462A Active KR102115203B1 (ko) 2011-08-16 2012-08-14 항-cd19 항체 및 질소 머스타드를 사용한 조합 요법
KR1020147006936A Ceased KR20140064873A (ko) 2011-08-16 2012-08-14 항-cd19 항체 및 질소 머스타드를 사용한 조합 요법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020197026462A Active KR102115203B1 (ko) 2011-08-16 2012-08-14 항-cd19 항체 및 질소 머스타드를 사용한 조합 요법
KR1020147006936A Ceased KR20140064873A (ko) 2011-08-16 2012-08-14 항-cd19 항체 및 질소 머스타드를 사용한 조합 요법

Country Status (24)

Country Link
US (3) US20140255427A1 (cg-RX-API-DMAC7.html)
EP (2) EP4062936A1 (cg-RX-API-DMAC7.html)
JP (1) JP6184952B2 (cg-RX-API-DMAC7.html)
KR (3) KR20200058583A (cg-RX-API-DMAC7.html)
CN (1) CN103732252B (cg-RX-API-DMAC7.html)
AU (1) AU2012296907B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013033919B1 (cg-RX-API-DMAC7.html)
CA (2) CA2841875C (cg-RX-API-DMAC7.html)
CY (1) CY1125122T1 (cg-RX-API-DMAC7.html)
DK (1) DK2744515T3 (cg-RX-API-DMAC7.html)
ES (1) ES2909722T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20220228T1 (cg-RX-API-DMAC7.html)
HU (1) HUE058350T2 (cg-RX-API-DMAC7.html)
IL (1) IL230293B (cg-RX-API-DMAC7.html)
LT (1) LT2744515T (cg-RX-API-DMAC7.html)
MX (1) MX354479B (cg-RX-API-DMAC7.html)
PL (1) PL2744515T3 (cg-RX-API-DMAC7.html)
PT (1) PT2744515T (cg-RX-API-DMAC7.html)
RS (1) RS63238B1 (cg-RX-API-DMAC7.html)
RU (1) RU2625222C2 (cg-RX-API-DMAC7.html)
SG (1) SG10201606785UA (cg-RX-API-DMAC7.html)
SI (1) SI2744515T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202200159T1 (cg-RX-API-DMAC7.html)
WO (1) WO2013024097A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2951427A1 (en) * 2014-06-16 2015-12-23 Xencor, Inc. Treatment for chronic lymphocytic leukemia (cll)
CA2986175A1 (en) * 2015-05-26 2016-12-01 Morphosys Ag Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof
AU2016311136B2 (en) 2015-08-21 2022-02-17 Incyte Corporation Combinations and uses thereof
EP3436070A4 (en) 2016-03-29 2019-11-27 University of Southern California AGAINST CANCER, CHIMERIC ANTIGEN RECEPTORS
MA45124B1 (fr) * 2016-05-30 2021-05-31 Morphosys Ag Procédés permettant de prédire un bénéfice thérapeutique d'une thérapie anti-cd19 chez des patients
IL266216B2 (en) * 2016-10-28 2023-09-01 Morphosys Ag Combination of anti-cd19 antibody with bcl-2 inhibitor and uses thereof
IL266892B2 (en) 2016-12-02 2025-10-01 Univ Southern California Artificial immune receptors and methods of using them
PL3630177T3 (pl) * 2017-05-31 2024-04-08 Morphosys Ag Paradygmat leczenia dla leczenia skojarzonego przeciwciałem anty-cd19 i wenetoklaksem
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
KR20240131370A (ko) * 2021-12-22 2024-08-30 인사이트 코포레이션 항-cd19 항체 요법을 위한 치료 패러다임

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US5686072A (en) 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
DE69909459T2 (de) * 1998-04-21 2004-05-27 Micromet Ag Cd19xcd3 spezifische polypeptide und deren verwendung
CN100358577C (zh) * 1999-05-07 2008-01-02 杰南技术公司 抗体在制备治疗哺乳动物自身免疫病的试剂中的用途
MXPA03002262A (es) 2000-09-18 2003-10-15 Idec Pharma Corp Terapia de combinacion para tratamiento de enfermedades autoinmunes usando una combinacion de anticuerpos inmunorreguladores/supresores de celulas b.
WO2003048731A2 (en) 2001-12-03 2003-06-12 Abgenix, Inc. Antibody categorization based on binding characteristics
US20080260731A1 (en) * 2002-03-01 2008-10-23 Bernett Matthew J Optimized antibodies that target cd19
EP1648512A4 (en) 2003-07-31 2009-01-21 Immunomedics Inc ANTI-CD19 ANTIBODIES
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
AR054094A1 (es) 2004-11-05 2007-06-06 Cephalon Inc Tratamientos de cancer
MX2007015944A (es) 2005-06-20 2008-03-07 Medarex Inc Anticuerpos cd19 y sus usos.
AU2006332155B2 (en) * 2005-12-30 2013-01-10 Cancer Research Technology Limited Anti-CD19 antibodies with reduced immunogenicity
AU2007285976B2 (en) * 2006-08-14 2011-08-18 Xencor, Inc Optimized antibodies that target CD19
CA2662340C (en) 2006-09-08 2016-08-02 Medimmune, Llc Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
DK2176298T3 (en) 2007-05-30 2018-02-12 Xencor Inc Methods and compositions for inhibiting CD32B-expressing cells
DK2211904T3 (en) 2007-10-19 2016-10-24 Seattle Genetics Inc Cd19-binding agents and uses thereof
EP2405937A4 (en) * 2009-01-16 2012-06-20 Glaxosmithkline Llc CANCER THERAPY USING A COMBINATION OF BENDAMUSTIN AND AN ANTIBODY AGAINST CD20
BRPI1005984A2 (pt) 2009-02-23 2016-10-04 Glenmark Pharmaceuticals Sa anticorpo humanizado ou fragmento do mesmo que se liga ao cd19 humano, acido nucleico isolado, vetor, célula hospedeira, método para produzir um anticorpo humanizado ou fragmento do mesmo que se liga à cd12 humano, composição, imunoconjugado, uso de um anticorpo humanizado ou fragmento do mesmo, artigo de manufatura e kit
CA2765080C (en) 2009-06-24 2018-07-17 The Feinstein Institute For Medical Research Methods for treating chronic lymphocytic leukemia
RU2012109451A (ru) * 2009-08-14 2013-09-27 Роше Гликарт Аг Комбинированная терапия на основе афукозилированного антитела к cd20 в сочетании с флударабином и/или митоксантроном
TWI409079B (zh) * 2009-08-14 2013-09-21 Roche Glycart Ag 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法
EP2501237A1 (en) * 2009-11-06 2012-09-26 Infinity Pharmaceuticals, Inc. Oral formulations of a hedgehog pathway inhibitor

Also Published As

Publication number Publication date
EP4062936A1 (en) 2022-09-28
CN103732252B (zh) 2017-11-10
PT2744515T (pt) 2022-05-19
EP2744515A1 (en) 2014-06-25
PL2744515T3 (pl) 2022-05-30
BR112013033919A2 (pt) 2017-12-19
HUE058350T2 (hu) 2022-07-28
US20140255427A1 (en) 2014-09-11
CN103732252A (zh) 2014-04-16
CA2841875A1 (en) 2013-02-21
WO2013024097A1 (en) 2013-02-21
RU2014103492A (ru) 2015-09-27
CA2841875C (en) 2021-11-02
DK2744515T3 (da) 2022-03-28
ES2909722T3 (es) 2022-05-10
AU2012296907B2 (en) 2017-01-05
MX354479B (es) 2018-03-07
IL230293B (en) 2019-01-31
US20240366756A1 (en) 2024-11-07
HRP20220228T1 (hr) 2022-05-13
KR20140064873A (ko) 2014-05-28
JP6184952B2 (ja) 2017-08-23
NZ617770A (en) 2016-01-29
SMT202200159T1 (it) 2022-05-12
US20200353077A1 (en) 2020-11-12
RS63238B1 (sr) 2022-06-30
SI2744515T1 (sl) 2022-05-31
LT2744515T (lt) 2022-04-25
MX2013014933A (es) 2014-04-16
CY1125122T1 (el) 2024-12-13
BR112013033919B1 (pt) 2022-11-16
SG10201606785UA (en) 2016-10-28
JP2014525926A (ja) 2014-10-02
EP2744515B1 (en) 2022-02-09
CA3137321A1 (en) 2013-02-21
KR102115203B1 (ko) 2020-05-28
RU2625222C2 (ru) 2017-07-12
KR20190107749A (ko) 2019-09-20

Similar Documents

Publication Publication Date Title
AU2022202796B2 (en) Combination of an anti-CD19 antibody and a Bruton's tyrosine kinase inhibitor and uses thereof
KR102115203B1 (ko) 항-cd19 항체 및 질소 머스타드를 사용한 조합 요법
KR102117202B1 (ko) 항ｃｄ19 항체 및 퓨린 유사체를 이용한 병용 요법
RU2767063C2 (ru) Комбинации и их использование
JP2014525926A5 (cg-RX-API-DMAC7.html)
AU2012296907A1 (en) Combination therapy with an anti - CD19 antibody and a nitrogen mustard
HK40081594A (en) Combination therapy with an anti-cd19 antibody and a nitrogen mustard

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20200519

Application number text: 1020197026462

Filing date: 20190909

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination